Evidence map›Paper›PMID 29475457›Full record

ArticleParasites & vectors2018

Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi.

Michelle N Clements, Paul L A M Corstjens, Sue Binder, Carl H Campbell, Claudia J de Dood, Alan Fenwick, Wendy Harrison, Donatien Kayugi, Charles H King, Dieuwke Kornelis and 6 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Parasites & vectors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. SCORE Studies on the Impact of Drug Treatment on Morbidity due toThe American journal of tropical medicine and hygiene · 2020
    Pooled it
  3. Trial
  4. Refining Diagnosis ofFrontiers in immunology · 2018
    Trial
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Detecting twoFrontiers in parasitology · 2024
    Article
  15. Article
  16. Reproducibility matters: intra- and inter-sample variation of the point-of-care circulating cathodic antigen test in twoPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Michelle N ClementsSchistosomiasis Control Initiative (SCI), Department of Infectious Disease Epidemiology, Imperial College London, London, UK. michelle.clements@imperial.ac.uk.
Paul L A M CorstjensDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands.
Sue BinderCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA.
Carl H CampbellCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA.
Claudia J de DoodDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands.
Alan FenwickSchistosomiasis Control Initiative (SCI), Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
Wendy HarrisonSchistosomiasis Control Initiative (SCI), Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
Donatien KayugiProgramme National Intégré de lutte contre les Maladies Tropicales Négligées et la Cécité (PNIMTNC), Ministère de la Santé Publique et de la Lutte contre le SIDA, Bujumbura, Burundi.
Charles H KingCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Dieuwke KornelisDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands.
Onesime NdayishimiyeProgramme National Intégré de lutte contre les Maladies Tropicales Négligées et la Cécité (PNIMTNC), Ministère de la Santé Publique et de la Lutte contre le SIDA, Bujumbura, Burundi.
Giuseppina OrtuSchistosomiasis Control Initiative (SCI), Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
Mariama Sani LamineSchistosomiasis Control Initiative (SCI), Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
Antonio ZivieriSchistosomiasis Control Initiative (SCI), Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
Daniel G ColleyCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA.
Govert J van DamDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands.
Imperial College London · GBLeiden University Medical Center · NLUniversity of Georgia · USMinistère de la Santé Publique · BICase Western Reserve University · US

Funding

Bill and Melinda Gates Foundation 50186
6 · The paper itself

Abstract

backgroundKato-Katz examination of stool smears is the field-standard method for detecting Schistosoma mansoni infection. However, Kato-Katz misses many active infections, especially of light intensity. Point-of-care circulating cathodic antigen (CCA) is an alternative field diagnostic that is more sensitive than Kato-Katz when intensity is low, but interpretation of CCA-trace results is unclear. To evaluate trace results, we tested urine and stool specimens from 398 pupils from eight schools in Burundi using four approaches: two in Burundi and two in a laboratory in Leiden, the Netherlands. In Burundi, we used Kato-Katz and point-of-care CCA (CCAB). In Leiden, we repeated the CCA (CCAL) and also used Up-Converting Phosphor Circulating Anodic Antigen (CAA).

methodsWe applied Bayesian latent class analyses (LCA), first considering CCA traces as negative and then as positive. We used the LCA output to estimate validity of the prevalence estimates of each test in comparison to the population-level infection prevalence and estimated the proportion of trace results that were likely true positives.

resultsKato-Katz yielded the lowest prevalence (6.8%), and CCAB with trace considered positive yielded the highest (53.5%). There were many more trace results recorded by CCA in Burundi (32.4%) than in Leiden (2.3%). Estimated prevalence with CAA was 46.5%. LCA indicated that Kato-Katz had the lowest sensitivity: 15.9% [Bayesian Credible Interval (BCI): 9.2-23.5%] with CCA-trace considered negative and 15.0% with trace as positive (BCI: 9.6-21.4%), implying that Kato-Katz missed approximately 85% of infections. CCAB underestimated disease prevalence when trace was considered negative and overestimated disease prevalence when trace was considered positive, by approximately 12 percentage points each way, and CAA overestimated prevalence in both models. Our results suggest that approximately 52.2% (BCI: 37.8-5.8%) of the CCAB trace readings were true infections.

conclusionsWhether measured in the laboratory or the field, CCA outperformed Kato-Katz at the low infection intensities in Burundi. CCA with trace as negative likely missed many infections, whereas CCA with trace as positive overestimated prevalence. In the absence of a field-friendly gold standard diagnostic, the use of a variety of diagnostics with differing properties will become increasingly important as programs move towards elimination of schistosomiasis. It is clear that CCA is a valuable tool for the detection and mapping of S. mansoni infection in the field and CAA may be a valuable field tool in the future.

Indexed as

Point-of-Care SystemsAnimalsAntigens, HelminthBayes TheoremBurundiChildClinical Laboratory TechniquesFecesFemaleGlycoproteinsHelminth ProteinsHumansMalePrevalenceSchistosoma mansoniSchistosomiasis mansoniAntigens, Helminthcirculating anodic antigen, Schistosoma mansoniGlycoproteinsHelminth ProteinsCAACCADiagnosticsKato-KatzLatent class analysisSchistosomiasis

Identifiers

PMID29475457
PMCPMC5824563
OpenAlexW2795123790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.